Phenotypes associated with this allele

• Allele Symbol: Nuak2^tm1Esu
• Allele Name: targeted mutation 1, Hiroyasu Esumi
• Allele ID: MGI:3809459
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Nuak2^tm1Esu/Nuak2^tm1Esu	B6.129S4-Nuak2^tm1Esu	MGI:3809485
ht2	Nuak2^tm1Esu/Nuak2^+	B6.129S4-Nuak2^tm1Esu	MGI:3809486

Genotype
MGI:3809485

hm1

• Allelic Composition: Nuak2^tm1Esu/Nuak2^tm1Esu
• Genetic Background: B6.129S4-Nuak2^tm1Esu

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

lethality throughout fetal growth and development, incomplete penetrance ( J:139603 )

• 90% or more show lethality at E16.5

• less than 10% are born alive

nervous system

exencephaly ( J:139603 )

• frequently observed in mice that die as embryos

digestive/alimentary system

abnormal crypts of Lieberkuhn morphology ( J:139603 )

• much higher number of aberrant crypt foci per mouse when treated with azoxymethane for 4 weeks starting a 4 weeks of age

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:139603 )

• much higher number of aberrant crypt foci per mouse when treated with azoxymethane for 4 weeks starting a 4 weeks of age

Genotype
MGI:3809486

ht2

• Allelic Composition: Nuak2^tm1Esu/Nuak2⁺
• Genetic Background: B6.129S4-Nuak2^tm1Esu

growth/size/body

increased body weight ( J:139603 )

• body weight greater than controls at 6 months

• body weight difference relative to controls becomes more pronounced with time

homeostasis/metabolism

increased circulating glucose level ( J:139603 )

• in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

decreased circulating free fatty acids level ( J:139603 )

• in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

increased circulating triglyceride level ( J:139603 )

• in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

digestive/alimentary system

abnormal crypts of Lieberkuhn morphology ( J:139603 )

• moderately elevated number of aberrant crypt foci per mouse when treated with azoxymethane for 4 weeks starting a 4 weeks of age

• increased number of aberrant foci and more aberrant crypts per focus in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

• number of aberrant crypt foci corrollated with body weight

increased intestinal adenoma incidence ( J:139603 )

• in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

• tubular adenomas found in more mice

• more tumors per mouse with tumors

• exophytic rounded or flattened polyps projecting into the intestinal lumen

neoplasm

increased intestinal adenoma incidence ( J:139603 )

• in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

• tubular adenomas found in more mice

• more tumors per mouse with tumors

• exophytic rounded or flattened polyps projecting into the intestinal lumen

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:139603 )

• moderately elevated number of aberrant crypt foci per mouse when treated with azoxymethane for 4 weeks starting a 4 weeks of age

• increased number of aberrant foci and more aberrant crypts per focus in mice treated for 8 weeks with azoxymethane starting at 6 months of age and tested 28 weeks after treatment

• number of aberrant crypt foci corrollated with body weight